MassMutual Private Wealth & Trust
DNTH icon

MassMutual Private Wealth & Trust’s Dianthus Therapeutics DNTH Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-4
Closed -$390 – 2383
2026
Q2 		$390 Buy
+4
New +$349 ﹤0.01% 2306

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

MassMutual Private Wealth & Trust's DNTH Position: Q3 2026 in Review

MassMutual Private Wealth & Trust sold out of Dianthus Therapeutics (DNTH) in Q3 2026, closing a stake of 4 shares — an estimated $390 sold.

MassMutual Private Wealth & Trust first reported a position in DNTH in Q2 2026 and held it in 1 quarter. The position peaked at $390 in Q2 2026. 123 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • MassMutual Private Wealth & Trust reported no remaining Dianthus Therapeutics position as of Q3 2026 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 4 Dianthus Therapeutics shares in Q3 2026, an estimated $390.
  • MassMutual Private Wealth & Trust first reported a position in Dianthus Therapeutics in Q2 2026 and held it in 1 quarter.
  • MassMutual Private Wealth & Trust's Dianthus Therapeutics position peaked at $390 in Q2 2026.
  • 123 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q3 2026, filed 5 Oct 2026.